within Pharmacolibrary.Drugs.ATC.B;

model B03XA02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.633333333333334e-07,
    adminDuration  = 600,
    adminMass      = 0.75 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.004900000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.004200000000000001,
    k12             = 0.038,
    k21             = 0.038
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B03XA02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Darbepoetin alfa is a synthetic analog of erythropoietin used to stimulate erythropoiesis. It is approved for the treatment of anemia associated with chronic kidney disease (CKD) and chemotherapy-induced anemia in cancer patients. It is longer-acting than recombinant human erythropoietin due to additional sialic acid groups.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adults with chronic kidney disease after intravenous and subcutaneous administration. Subjects included both male and female patients, 18 to 75 years old, with stable renal function.</p><h4>References</h4><ol><li><p>Ibbotson, T, &amp; Goa, KL (2001). Darbepoetin alfa. <i>Drugs</i> 61(14) 2097–2106. DOI:<a href=\"https://doi.org/10.2165/00003495-200161140-00007\">10.2165/00003495-200161140-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11735636/\">https://pubmed.ncbi.nlm.nih.gov/11735636</a></p></li><li><p>Heatherington, AC, et al., &amp; Schueller, J (2006). Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. <i>Clinical pharmacokinetics</i> 45(2) 199–211. DOI:<a href=\"https://doi.org/10.2165/00003088-200645020-00005\">10.2165/00003088-200645020-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16485917/\">https://pubmed.ncbi.nlm.nih.gov/16485917</a></p></li><li><p>Roberts, JK, et al., &amp; Sherwin, CM (2015). Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. <i>Clinical pharmacokinetics</i> 54(12) 1237–1244. DOI:<a href=\"https://doi.org/10.1007/s40262-015-0286-y\">10.1007/s40262-015-0286-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25989868/\">https://pubmed.ncbi.nlm.nih.gov/25989868</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B03XA02;
